18.05.2022 14:45:00
|
Neogen® Launches Enhanced Quantitative Peanut ELISA Assay
New assay provides enhanced detection of high-priority peanut allergen in a wide variety of matrices
LANSING, Mich., May 18, 2022 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced today that the company has released an enhanced version of the Veratox® for Peanut allergen test, which optimizes sensitivity and flexibility across sample types while maintaining the rapid time-to-result and simple testing procedure standards set by the Veratox product line.
Neogen's new Veratox VIP (Veratox Improvement Platform) for Peanut assay is able to rapidly quantify low levels of peanut protein residues in food products, ingredients, and clean-in-place rinses.
"As the demand for plant-based foods continues to increase, we have seen peanut proteins being processed in more new and creative ways than ever before. However, peanut remains one of the highest-priority allergens in the food industry," said John Adent, Neogen's President and CEO. "It was very important that we offer a solution that gives producers confidence as they navigate this changing landscape. The new Veratox VIP for Peanut assay is very sensitive and able to detect low levels of peanut protein while remaining fast and easy to use."
This innovative quantitative test utilizes the pairing of a unique antibody combination and a modified extraction process to robustly detect levels of peanut protein down to 0.25 ppm. This product has been validated in a wide variety of product types, including both minimally and further-processed products. This flexibility makes the assay appropriate across different food manufacturing and laboratory environments.
About Neogen
Neogen Corporation develops and markets comprehensive solutions dedicated to food and animal safety, operating with the intention to "everyday, protect the people and animals we care about." The company's Food Safety segment markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases, and sanitation concerns. Neogen's Animal Safety segment is a leader in the development of genomic solutions along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care, and disinfectants, as well as rodent and insect control solutions.
CONTACT: Max Wolf, Product Manager, 800-234-5333, mwolf@neogen.com
View original content:https://www.prnewswire.com/news-releases/neogen-launches-enhanced-quantitative-peanut-elisa-assay-301550076.html
SOURCE NEOGEN Corporation
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Neogen Corp.mehr Nachrichten
12.12.24 |
NASDAQ Composite Index-Wert Neogen-Aktie: So viel hätten Anleger an einem Neogen-Investment von vor einem Jahr verloren (finanzen.at) | |
11.12.24 |
Börse New York in Grün: NASDAQ Composite klettert am Nachmittag (finanzen.at) | |
11.12.24 |
Freundlicher Handel: NASDAQ Composite legt am Mittag zu (finanzen.at) | |
05.12.24 |
NASDAQ Composite Index-Wert Neogen-Aktie: So viel Verlust hätte eine Investition in Neogen von vor 10 Jahren bedeutet (finanzen.at) | |
03.12.24 |
NASDAQ Composite-Handel aktuell: NASDAQ Composite am Mittag im Aufwind (finanzen.at) | |
28.11.24 |
NASDAQ Composite Index-Wert Neogen-Aktie: So viel hätten Anleger an einem Neogen-Investment von vor 5 Jahren verloren (finanzen.at) | |
26.11.24 |
NASDAQ-Handel: NASDAQ Composite notiert am Nachmittag im Plus (finanzen.at) | |
26.11.24 |
Börse New York in Grün: So bewegt sich der NASDAQ Composite am Mittag (finanzen.at) |